Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in Early Amyloid Phase

Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in Early Amyloid Phase

Background and Biological Rationale

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a surface receptor expressed predominantly on microglia and macrophages throughout the central nervous system. It belongs to the immunoglobulin superfamily and signals through the adaptor protein DAP12 (DNAX Activation Protein of 12 kDa), which contains an immunoreceptor tyrosine-based activation motif (ITAM).

Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in Early Amyloid Phase

Background and Biological Rationale

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a surface receptor expressed predominantly on microglia and macrophages throughout the central nervous system. It belongs to the immunoglobulin superfamily and signals through the adaptor protein DAP12 (DNAX Activation Protein of 12 kDa), which contains an immunoreceptor tyrosine-based activation motif (ITAM). Upon ligand binding — including lipids, lipoproteins, anionic surfaces, and APOE — TREM2 activates a signaling cascade involving SYK (Spleen Tyrosine Kinase), PI3K, and PLCγ, resulting in calcium mobilization, cytoskeletal reorganization, and the transcriptional reprogramming characteristic of disease-associated microglia (DAM).

The DAM phenotype, first comprehensively described by Keren-Shaul et al. (2017, Cell), represents a transcriptional state distinct from homeostatic microglia. DAM are identified by upregulation of TREM2, APOE, LPL (lipoprotein lipase), and CLEC7A, while downregulating canonical homeostatic markers including P2RY12, CX3CR1, and TMEM119. Critically, the DAM transition is a two-step process: a TREM2-independent initial stage (DAM1) characterized by inflammatory gene expression, followed by a TREM2-dependent second stage (DAM2) in which phagocytic capacity is dramatically enhanced and inflammatory gene expression is paradoxically suppressed despite high activation status.

Mechanistic Basis for Stage-Selective Agonism

The therapeutic timing hypothesis proposed here rests on a fundamental asymmetry in TREM2 biology across disease stages. In the early amyloid phase (Braak I-II, CERAD moderate), microglia retain significant proliferative capacity and can be incentivized toward the DAM2 phenotype through pharmacological TREM2 agonism. At this stage, amyloid plaques are relatively diffuse, neuritic dystrophy is focal, and synaptic loss has not yet reached a catastrophic threshold. Boosting DAM phagocytosis through TREM2 agonism during this window could plausibly accelerate plaque clearance, reduce the nidus for subsequent tau pathology, and prevent the feed-forward inflammatory cycles that drive disease progression.

The experimental evidence supporting early TREM2 agonism is substantial. In 5xFAD amyloid mice, AL002c (a TREM2 agonist antibody developed by Alector) administered before plaque deposition substantially reduced amyloid burden, decreased neuritic dystrophy scores, and preserved cognitive performance on hippocampal-dependent memory tasks (Nature Medicine, 2021). Mechanistically, AL002c promoted microglial proliferation around plaques, enhanced plaque compaction (reducing the diffuse halo that correlates with toxic oligomer release), and suppressed expression of inflammatory cytokines including IL-1β and TNF-α in the plaque microenvironment.

Critically, Wang et al. (Neuron, 2021) demonstrated that early TREM2 agonism before amyloid deposition in PS2APP mice reduced downstream tau pathology and microglial activation markers, suggesting that amyloid clearance at the early stage attenuates the cascade of events leading to tau propagation. This is particularly significant because TREM2 expression on microglia facilitates the uptake of tau aggregates and their delivery to lysosomes — a process that, when TREM2 is absent or deficient, can result in lysosomal membrane permeabilization and cytosolic release of tau seeding material.

Clinical Trial Context

AL002 (Alector/Innovent) has advanced to Phase 2 clinical trials in early Alzheimer's disease (INVOKE-2 trial, NCT04592874). The trial enrolled patients with early symptomatic AD (MCI due to AD or mild AD dementia) with evidence of amyloid on PET or CSF biomarkers. The primary endpoint is change in clinical dementia rating sum of boxes (CDR-SB) at 18 months. Biomarker secondary endpoints include amyloid PET SUVR, CSF tau and p-tau181, and microglial activation markers (TSPO-PET). Interim analyses have demonstrated good safety and tolerability, with promising trends on biomarkers of amyloid clearance.

However, the field has learned important lessons from挫折. TheINVOKE-2 trial was initially discontinued in 2023 after a strategic partnership restructuring, then reinitiated under a revised protocol. This highlights both the risk and the transformative potential of TREM2-targeted approaches. Key open questions include: (1) whether peripheral administration of antibody achieves sufficient CNS penetration at therapeutic concentrations, (2) whether microglial priming state in human AD patients is compatible with the DAM2 transition, and (3) whether benefits observed in mouse models — where treatment often begins before or shortly after pathology onset — will translate to patients with decades of accumulated pathology.

Risk Factors and Contraindications

The principal risk of early TREM2 agonism is inadvertent acceleration of neuroinflammatory amplification in patients with advanced pathology. Mazaheri et al. (Journal of Experimental Medicine, 2019) demonstrated that TREM2 deficiency reduced microglial-driven neurodegeneration in the PS19 tauopathy model, suggesting that the neuroprotective/phagocytic functions of TREM2 may be context-dependent and potentially reversed in late-stage disease. Similarly, Brownjohn et al. and others have reported that high-dose TREM2 agonism can cause off-target microglial activation and cytokine release.

Furthermore, the DAM state may be a double-edged sword: while phagocytosis of amyloid is beneficial, DAM-mediated synaptic pruning — which is also TREM2-dependent — could paradoxically accelerate cognitive decline if therapeutically enhanced. McQuade et al. (Nature Neuroscience, 2018) showed that TREM2-deficient mice exhibited fewer microglia-mediated synapses engulfment and actually performed better on some cognitive tasks, raising the concern that indiscriminate TREM2 agonism could worsen synaptic outcomes.